Compare Galapagos NV with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 31.40% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -52.79
- INTEREST(HY) At EUR 1.31 MM has Grown at 154.37%
- OPERATING PROFIT(Q) Lowest at EUR -44.04 MM
- OPERATING PROFIT MARGIN(Q) Lowest at -165.14 %
2
Risky -
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-83.91%
0%
-83.91%
6 Months
-86.97%
0%
-86.97%
1 Year
-84.95%
0%
-84.95%
2 Years
-73.15%
0%
-73.15%
3 Years
-70.29%
0%
-70.29%
4 Years
-52.87%
0%
-52.87%
5 Years
-42.3%
0%
-42.3%
Galapagos NV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.69%
EBIT Growth (5y)
31.40%
EBIT to Interest (avg)
-52.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.20
Sales to Capital Employed (avg)
0.20
Tax Ratio
1.67%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.07%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
3
Industry P/E
Price to Book Value
0.59
EV to EBIT
-2.32
EV to EBITDA
-2.32
EV to Capital Employed
-4.56
EV to Sales
-0.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
16.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.07%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,112.20
275.60
303.56%
Operating Profit (PBDIT) excl Other Income
521.50
-183.60
384.04%
Interest
1.70
1.70
Exceptional Items
-222.50
72.50
-406.90%
Consolidate Net Profit
319.50
-1.30
24,676.92%
Operating Profit Margin (Excl OI)
422.30%
-826.70%
124.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 303.56% vs 14.98% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 24,676.92% vs 67.50% in Dec 2024
About Galapagos NV 
Galapagos NV
Pharmaceuticals & Biotechnology
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
Company Coordinates 
Company Details
Generaal De Wittelaan 3 , MALINES (MECHELEN) None : 2800
Registrar Details






